MK 8776
Alternative Names: MK-8776; SCH 900776Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Antineoplastics; Pyrazoles; Pyrimidines
- Mechanism of Action Cell cycle inhibitors; Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cancer; Lymphoma; Solid tumours
Most Recent Events
- 01 May 2013 Phase-II clinical trials in Acute myeloid leukaemia (combination therapy) in USA (IV)
- 21 Feb 2012 Schering-Plough terminates a phase I trial in Leukaemia (combination therapy) in USA (NCT00907517)
- 22 Jun 2011 Schering-Plough completes a phase I trial in Solid tumours and Lymphomas (combination therapy) in US (NCT00779584)